$Humacyte (HUMA.US)$
Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues
Humacyte (Nasdaq: HUMA) has been granted U.S. Patent No. 12,195,711 for its 'Drawer System for Cultivating Tissue,' covering key aspects of their bioreactor manufacturing system until 2040. The patent specifically relates to the production of Symvess, their first-in-class bioengineered human tissue designed as a universally implantable vascular conduit.
The compa...

$Humacyte (HUMA.US)$ Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues
4 MINUTES AGO, 8:00 AM EST
VIA GLOBENEWSWIRE
Patent provides coverage into 2040 for key aspects of the bioreactor manufacturing system –
– Symvess, the acellular tissue engineered vessel, is manufactured in this patented system –

$Humacyte (HUMA.US)$
Hospitals Already Adopting Humacyte's Revolutionary Bioengineered Blood Vessel - What Makes Symvess Different?

$Humacyte (HUMA.US)$ Order 66

$Humacyte (HUMA.US)$ hard 8

$Humacyte (HUMA.US)$
Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs
Humacyte (Nasdaq: HUMA) and Pluristyx have expanded their partnership to advance the development of the BioVascular Pancreas (BVP™), designed to treat insulin-dependent diabetes. Pluristyx will provide gene-edited PluriBank™ iPSC lines with blocked Human Leukocyte Antigen (HLA) markers expression, using their clinical-grade Mad7 gene editing technology.
...

$Humacyte (HUMA.US)$ Reuters
1 min ago
Humacyte and Pluristyx Announce Gene Editing Partnership to Support Biovascular Pancreas (Bvp™) Development Using Ipscs

Potentially breaking out from a downward sloping Raff Regression model. I am long $Humacyte (HUMA.US)$ .

$Humacyte (HUMA.US)$ Finally going up for real?